261 Mountain View Dr
Colchester, VT 05446
License #: TLAB0030
802-767-7256
info@onwardanalytics.biz

Certificate of Analysis

Client Name: Tilia Processing LLC
License Number: MANU0012

Sample ID: 20261007-37960
Sample Name: SpringDrops: Brighten
Sample Lot: MANU0012-085-09
Sample Matrix: Tinctures
Date Received: 10/7/2026
Date Reported: 10/13/2026
Date Tested: 10/12/2026



Total Cannabinoids

	%	mg/g	mg/mL	mg/unit
Total THC:	**1.241**	**12.415**	**11.895**	**356.850**
Total CBD:	**--**	**--**	**--**	**0.000**
Total Cannabinoids:	**1.576**	**15.765**	**15.105**	**453.150**
Unit Volume (mL): 30				

Total theoretical CBD % = (CBD%) + (CBDA% * 0.877)
Total theoretical THC % = (delta-9-THC%) + (THCA% * 0.877)

Potency

Standard potency analysis utilizing High Performance Liquid Chromatography (HPLC; SOP-102-OA) | **Test ID: #124889**

Analyte	%	mg/g	mg/mL	mg/unit	LOD (mg/g)	LOQ (mg/g)
CBC	ND	ND	ND	ND	0.0003	0.0040
CBCA	ND	ND	ND	ND	0.0002	0.0040
CBD	ND	ND	ND	ND	0.0008	0.0040
CBDA	ND	ND	ND	ND	0.0002	0.0040
CBDV	ND	ND	ND	ND	0.0008	0.0040
CBDVA	ND	ND	ND	ND	0.0001	0.0040
CBG	0.335	3.350	3.210	96.300	0.0009	0.0040
CBGA	ND	ND	ND	ND	0.0001	0.0040
CBN	< LOQ	< LOQ	< LOQ	<LOQ	0.0004	0.0040
CBNA	ND	ND	ND	ND	0.0002	0.0040
D8 THC	ND	ND	ND	ND	0.0012	0.0040
D9 THC	1.242	12.415	11.895	356.850	0.0016	0.0049
D10 THC	ND	ND	ND	ND	0.0004	0.0040
THCA	ND	ND	ND	ND	0.0002	0.0040
THCV	ND	ND	ND	ND	0.0016	0.0049
THCVA	ND	ND	ND	ND	0.0002	0.0040

* Measurements of uncertainty available on request

Callie Chapman
Lab Director
10/13/2026

Rev. 1	Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; (e) OA does not utilize decision rules, results are reported as simple acceptance. MOU is not taken into account for statements of conformity (e.g. regulatory action limits "pass/fail"); and (f) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.